Related Experiment Video
Updated: Jun 4, 2026
08:22
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
microRNAs in hypertrophy and heart failure
Michael V G Latronico1, Gianluigi Condorelli
1Scientific and Technological Park, Casa di Cura MultiMedica - Istituto di Ricovero e Cura a Carattere Scientifico.
Experimental Biology and Medicine (Maywood, N.J.)
|February 16, 2011
Summary
This review summarizes recent advances in understanding heart-related microRNAs (miRNAs) and their crucial role in regulating cardiac hypertrophy and heart failure. These findings highlight miRNAs as key players in cardiovascular disease progression.
Area of Science:
- Cardiovascular Biology
- Molecular Genetics
- Non-coding RNA Research
Background:
- MicroRNAs (miRNAs) are short, non-coding RNA molecules with critical regulatory functions.
- miRNAs are integral components of complex gene regulatory networks.
- Their involvement in cardiovascular physiology and pathology is increasingly recognized.
Purpose of the Study:
- To provide an updated review of recent advancements in the field of cardiac microRNAs.
- To focus on the specific roles of miRNAs in hypertrophic growth and the development of heart failure.
- To consolidate current knowledge on miRNA-mediated regulation in cardiovascular diseases.
Main Methods:
- Literature review of scientific publications from the past two years.
- Focus on studies investigating microRNA function in cardiac hypertrophy models.
- Analysis of research on microRNAs implicated in heart failure pathogenesis.
Main Results:
- Significant progress has been made in identifying key miRNAs involved in cardiac remodeling.
- Specific miRNAs have been linked to the progression of hypertrophic cardiomyopathy.
- Emerging evidence implicates miRNAs in the pathophysiology of heart failure.
Conclusions:
- MicroRNAs are pivotal regulators in the context of cardiac hypertrophy and heart failure.
- Continued research into cardiac miRNAs offers potential for novel therapeutic strategies.
- Understanding miRNA networks is essential for advancing cardiovascular medicine.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...